Oncology Blood Testing Industry is poised for success, expected to generate US$ 18,278.2 Million by 2032, according to FMI

The Oncology blood testing industry refers to the market for diagnostic tests that analyze blood samples to detect and monitor various types of cancers. These tests are used to identify specific biomarkers or genetic alterations associated with cancer, aiding in early detection, treatment selection, and monitoring of the disease.

The market for oncology blood testing has experienced significant growth in recent years due to several factors, including advancements in technology, increasing cancer prevalence, and the need for non-invasive and more accurate diagnostic methods. These blood tests offer several advantages over traditional tissue biopsies, such as being less invasive, providing real-time monitoring, and allowing for repeated testing.

Discover Our Expert Analysis with Our Sample Request! https://www.futuremarketinsights.com/reports/sample/rep-gb-6449

According to projections, the market for oncology blood testing will be worth US$ 3,851.7 million in 2022 and US$ 18,278.2 million by 2032. The market is anticipated to expand significantly during the forecast period at a CAGR of 15.2%.

The oncology blood testing industry is a rapidly growing sector within the healthcare industry. Here are some key takeaways about this market:

• Market Growth: The oncology blood testing industry has experienced significant growth in recent years and is expected to continue growing at a robust rate. Factors such as increasing prevalence of cancer, advancements in diagnostic technologies, and rising demand for personalized medicine are driving market expansion.
• Non-Invasive Testing: One of the major developments in oncology blood testing is the shift towards non-invasive or liquid biopsy testing methods. These tests analyze circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and other biomarkers present in the blood to detect and monitor cancer. Non-invasive testing is gaining popularity due to its convenience, cost-effectiveness, and ability to provide real-time information about a patient’s cancer status.
• Early Detection and Diagnosis: Oncology blood tests play a crucial role in early detection and diagnosis of cancer. They enable healthcare professionals to identify the presence of cancer at an early stage, even before the onset of symptoms. Early detection facilitates timely intervention and improves treatment outcomes.
• Monitoring Treatment Response: Blood tests are also used for monitoring the effectiveness of cancer treatment. They help healthcare providers assess treatment response, detect minimal residual disease, and identify any genetic mutations or resistance mechanisms that may develop during the course of treatment. This allows for adjustments in treatment plans to optimize patient care.
• Biomarker Discovery and Research: The field of oncology blood testing is driving significant research and discovery of new biomarkers associated with cancer. Biomarkers are specific molecules or genetic alterations that can indicate the presence of cancer, predict disease progression, or determine treatment response. Ongoing research aims to identify and validate novel biomarkers that can improve the accuracy and reliability of blood-based cancer diagnostics.

Customize Your Knowledge: Unlock Targeted Insights to Drive Growth in the Oncology blood testing industry! https://www.futuremarketinsights.com/customization-available/rep-gb-6449

Oncology Blood Testing: Market Dynamics

Increasing capability of early detection of cancer via oncology blood tests that enables instant treatment decisions, growing prevalence of cancer among people over the globe, increasing production of oncology blood testing assays and kits with capability of being efficient diagnostic tool for cancer detection in blood are some of the major factors expected to drive the growth of oncology blood testing industry.

Introduction of rapid and technologically advanced liquid biopsy assay, growing awareness about less invasive blood diagnostic tests and increased expenditure in oncology blood screening R&D activities is further propelling the growth of oncology blood testing industry. Also, rise in demand for oncology blood testing in the hospitals and diagnostic laboratories is also expected to drive the growth of market. However, large number of diagnostic tools to detect cancer using blood sample are still under development and clinical trial stage, and are not available commercially, thereby restraining the oncology blood testing industry growth.

Oncology blood testing industry: Region-wise Outlook

On the basis of geography, global Oncology blood testing industry is segmented into seven key regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan, and Middle East & Africa. North America is projected to hold largest shares in the global oncology blood testing industry primarily due to growing population of cancer patients in the region that necessitates need to meet high demand for advanced diagnostic technologies to prevent, diagnose and treat cancer.

North America is followed by Europe which registers second largest shares in global oncology blood testing industry worldwide owing to the easy regulatory approval for in vitro cancer diagnostics in Europe. However, Asia Pacific is expected to experience a robust growth over the forecast period in global oncology blood testing industry.

Oncology blood testing industry: Key Players

Some of the key players present in global Oncology blood testing industry are

• Guardant Health Inc.,
• Trovagene Inc.,
• Genomic Health Inc.,
• Foundation Medicine Inc.,
• Exosome Diagnostics,
• Pathway Genomics Corporation

Unlock Exclusive Market Segments Insights: Buy Now! https://www.futuremarketinsights.com/checkout/6449

Key Segments:

By Test Type:

• CBC (Complete Blood Count) Test
• Blood Protein Test
• Tumor Marker Test
• CTC (Circulating Tumor Cells) – based Test
• NIPT (Non-Invasive Prenatal Testing) Test
• Liquid Biopsy Assays
• Exom-Based Liquid Biopsy

By Application:

• Lung Cancer
• Breast Cancer
• Colon Cancer
• Melanoma
• Ovarian Cancer
• Gastro-Intestinal Stromal Tumor (GIST)

By End User:

• Hospitals
• Specialty Clinics
• Diagnostic Laboratories

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube